OpGen, Inc. (OPGN)
- Previous Close
0.5980 - Open
0.5900 - Bid 0.5775 x 200
- Ask 0.6362 x 200
- Day's Range
0.5900 - 0.6199 - 52 Week Range
0.1650 - 3.8400 - Volume
49,457 - Avg. Volume
1,728,596 - Market Cap (intraday)
7.365M - Beta (5Y Monthly) -0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-6.2500 - Earnings Date Apr 24, 2024 - Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
www.opgen.comRecent News: OPGN
Performance Overview: OPGN
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OPGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OPGN
Valuation Measures
Market Cap
7.18M
Enterprise Value
19.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.09
Price/Book (mrq)
2.68
Enterprise Value/Revenue
6.33
Enterprise Value/EBITDA
-0.87
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.91%
Return on Equity (ttm)
-314.92%
Revenue (ttm)
3.07M
Net Income Avi to Common (ttm)
-26.16M
Diluted EPS (ttm)
-6.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
292.64k
Total Debt/Equity (mrq)
468.95%
Levered Free Cash Flow (ttm)
-12.7M